Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PAM | P19021 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PARL | Q9H300 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499428 | 0.91 | KMT2A (0.46) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL4738882 | 0.90 | LMNA (0.51) | KMT2AMAPK1HPGDALDH1A1TSHR | |
| SCHEMBL19658177 | 0.88 | KMT2A (0.50) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL22415045 | 0.86 | KMT2A (0.46) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL25916425 | 0.86 | KMT2A (0.49) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL31225579 | 0.86 | FAAH (0.53) | KMT2AMAPK1HPGDALDH1A1PKM | |
| SCHEMBL436079 | 0.85 | TDP1 (0.54) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL5852228 | 0.84 | CA2 (0.46) | KMT2AMAPK1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL19658180 | 0.84 | KMT2A (0.41) | KMT2AMAPK1HPGDALDH1A1PKM | |
| SCHEMBL5019569 | 0.83 | KMT2A (0.41) | KMT2AMAPK1HPGDALDH1A1PAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032585-B1 | DEOXYHYPUSINE REAGENT AND PEPTIDES | UNIV FLORIDA (US) | 2004-11-24 | — | — | EP | claimed |
| US-6258931-B1 | SYNTHESIZING DEOXYHYPUSINE DERIVATIVE BY USING ESTER OF DIPROTECTED LYSINE, DEBLOCKING ONE NITROGEN, CONDENSING WITH 3-CYANOPROPANAL, REDUCING TO A TRIAMINE, PROTECTING FREE AMINO GROUPS, DEBLOCKING AGAIN, AND ACYLATING THE FREE AMINO GROUP | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2001-07-10 | — | — | US | claimed |
| EP-1032585-A1 | DEOXYHYPUSINE REAGENT AND PEPTIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000011020-A9 | DEOXYHYPUSINE REAGENT AND PEPTIDES | UNIV FLORIDA (US) | 2000-08-10 | — | — | WO | claimed |
| WO-2000011020-A1 | DEOXYHYPUSINE REAGENT AND PEPTIDES | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2000-03-02 | — | — | WO | claimed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4218833-A1 | LABELING OF ANTIBODIES | Whitehead Institute for Biomedical Research (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4204441-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3359573-B1 | LABELING OF ANTIBODIES | THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RES (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11530250-B2 | Tyrosine-specific functionalized insulin and insulin analogs | MERCK SHARP & DOHME LLC (US) | 2022-12-20 | — | — | US | disclosed |
| EP-0099747-B1 | C-23-MODIFIED DERIVATIVES OF 5-0-MYCAMINOSYL TYLONOLIDE | ELI LILLY AND COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0099746-B1 | C-23-MODIFIED DERIVATIVES OF MACROLIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-10-22 | — | — | EP | disclosed |
| US-4459290-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1984-07-10 | — | — | US | disclosed |
| US-4452784-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1984-06-05 | — | — | US | disclosed |
| US-4443436-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1984-04-17 | — | — | US | disclosed |
| EP-0099746-A1 | C-23-modified derivatives of macrolide antibiotics | ELI LILLY AND COMPANY (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0099747-A1 | C-23-modified derivatives of 5-0-mycaminosyl tylonolide | ELI LILLY AND COMPANY (US) | 1984-02-01 | — | — | EP | disclosed |
| US-4401594-A | PROTEOLYTIC ENZYME INHIBIJTORS; CARDIOVASCULAR AND MUSCULAR DISORDERS | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530250-B2 | Tyrosine-specific functionalized insulin and insulin analogs | IRS1, IGF1R, INSR | KMT2A 2835/4885MAPK1 423/4885HPGD 3148/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | KMT2A 4174/4885MAPK1 3170/4885HPGD 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.